UpHealth, Inc. (“UpHealth” or the “Company”) (NYSE: UPH), a global
digital health company delivering technology platforms,
infrastructure, and services to modernize care delivery and health
management, today announced financial results for the first quarter
ended March 31, 2023.
UpHealth Chief Executive Officer Sam Meckey
said, “I am very proud of our team’s efforts which contributed to
our top line growth of 17% to $42.1 million in the first quarter of
2023 over the first quarter of 2022, gross margin expansion to 54%
and our notable $7.9 million improvement in Adjusted EBITDA. We
continue to focus on preserving capital and executing against our
strategic plan, while improving free cash flow generation. We took
action to solidify our balance sheet by completing the sale of
Innovations Group, Inc. (“IGI”), delivering an additional $56.0
million in gross proceeds in the second quarter. We also secured
PIPE financing, with gross proceeds of $4.5 million. These
actions provide us with significant liquidity to run the business
going forward. Operationally, we continue to right-size our
businesses. We have reduced our headcount by 12% since we began our
turnaround efforts in August. Additionally, we have reduced our
external vendor spend and discontinued a number of internal
initiatives that were not producing results. These cost savings are
a direct result of our previously stated goal of aligning expenses
and costs with the current revenues of our business. These
necessary initiatives have led to a leaner, more focused company,
which has allowed us to build the needed foundation to support our
go forward growth initiatives. I am very pleased with the progress
made to date, and with our first quarter results, which represent a
significant step forward in the recalibration of our business in
2023.”
First Quarter 2023 Highlights:
- Revenues for the first quarter of
2023 were $42.1 million, representing an increase of 17% compared
to revenues for the first quarter of 2022 of $36.0 million, an
increase of 4% compared to revenues for the fourth quarter of 2022
of $40.5 million, and an increase of 29% compared to pro forma
revenues for the first quarter of 2022 (excluding Glocal revenue)
of $32.7 million. Revenues by segment were as follows:
- Virtual Care Infrastructure revenues were $17.5 million (41% of
total revenues), representing an increase of 12% compared to
revenues for the first quarter of 2022 of $15.6 million, primarily
due to an increase in minutes from both new and existing U.S.
Telehealth customers. During the three months ended March 31, 2023,
no revenues were recognized for Glocal as a result of its
deconsolidation in July 2022.
- Services revenues were $20.8 million (49% of total revenues),
representing an increase of 17% compared to revenues for the first
quarter of 2022 of $17.7 million, primarily due to higher census
and improved payor mix at UpHealth Behavioral™ and an increase
in the volume and sales price of prescriptions in the Pharmacy
business.
- Integrated Care Management revenues were $3.9 million (9% of
total revenues), representing an increase of 48% compared to
revenues for the first quarter of 2022 of $2.6 million, primarily
due to growth in professional services revenue from existing
customers.
- Gross margin expanded to 54% for the
first quarter of 2023 from 39% for the first quarter of 2022. Gross
margins by segment were as follows:
- Virtual Care Infrastructure gross margin was 58%, an increase
from 42% for the first quarter of 2022, primarily due a shift in
mix from audio to video minutes in the U.S. Telehealth business,
and no recognition of lower margin revenue for Glocal during the
three months ended March 31, 2023 as a result of its
deconsolidation in July 2022.
- Services gross margin was 48%, an increase from 33% for the
first quarter of 2022, primarily due to higher census and improved
mix of services at UpHealth Behavioral™ and higher sales
prices of prescriptions in the Pharmacy business.
- Integrated Care Management gross margin was 67%, an increase
from 63% for the first quarter of 2022, primarily due to an
increase in professional services performed at higher margins.
- Operating loss for the first quarter of
2023 was $0.8 million, a 96% improvement compared to operating loss
in the first quarter of 2022 of $17.9 million. This improvement
primarily resulted from the deconsolidation of Glocal during the
third quarter of 2022 and a reduction in the amortization of
intangible assets due to impairments recorded in 2022.
- Net loss attributable to UpHealth, Inc.
for the first quarter of 2023 was $8.1 million, a 54% improvement
compared to net loss attributable to UpHealth, Inc. for the first
quarter of 2022 of $17.4 million.
- Adjusted EBITDA for the first quarter
of 2023 improved by $7.9 million, to $6.6 million, compared to
Adjusted EBITDA for the first quarter of 2022 of $(1.3)
million.
- Headcount decreased by 12% since we
began our turnaround efforts in August 2022.
- On March 13, 2023 UpHealth closed a
private placement for the sale of 1,650,000 shares of UpHealth’s
common stock, pre-funded warrants to purchase an additional
1,350,000 shares of UpHealth's common stock, and warrants to
purchase up to 6,000,000 shares of UpHealth's common stock,
resulting in total gross proceeds of approximately
$4.5 million before deducting placement agent commissions and
other offering expenses.
- On May 11, 2023, UpHealth completed the
strategic sale of IGI to Belmar Pharma Solutions for gross proceeds
of $56.0 million, which adds significant liquidity to UpHealth’s
balance sheet in the second quarter of 2023. This transaction
represents execution against UpHealth's new strategic vision and
focus on scalable growth opportunities in the U.S. Telehealth,
UpHealth Behavioral™, and Integrated Care Management
businesses.
Certain prior period amounts have been
reclassified to conform with our current period presentation.
Please refer to the discussion and tables under “Non-GAAP Financial
Information.”
Balance Sheet and Cash Flow
On March 31, 2023, UpHealth reported $13.3 million of cash and
cash equivalents. This does not include approximately $7.0 million
in cash in India that is held in a bank account which the Emergency
Arbitrator has ordered cannot be accessed by Glocal or UpHealth.
Subsequent to quarter end, UpHealth completed the strategic sale of
IGI to Belmar Pharma Solutions for gross proceeds of $56.0
million.
Fiscal 2023 Financial Outlook
We continue to expect 2023 revenues to be in the
range of $127 to $135 million. This represents growth of 5% to 12%
over pro forma 2022 revenue of $121 million. For comparison
purposes, both 2023 estimated revenue and 2022 pro forma revenue
include five months of operations for IGI and exclude the Glocal
operations. In 2023, we expect gross margins to be in
the range of 43% to 45% and adjusted EBITDA to be in the range of
$7 to $10 million.
Conference Call
UpHealth management will host a live question-and-answer session
with investors and analysts beginning at 5:00 p.m. Eastern Time
today, May 11, 2023. The call can be accessed live over the
telephone by dialing (800-920-5564) from the U.S. or International
callers can dial (212) 231-2931. There will also be a simultaneous,
live webcast available on the Investor Relations section of the
Company's web site at
https://investors.uphealthinc.com/events-and-presentations/default.aspx
or directly here. The webcast will be archived for approximately 30
days.
Inducement Grant
UpHealth’s Compensation Committee of its Board of Directors
approved, effective as of May 9, 2023, the grant under Section
303A.08 of the NYSE Listed Company Manual of an employment
inducement award consisting of restricted stock units (“RSUs”)
covering 200,000 shares of UpHealth common stock to its new Chief
Legal Officer, Jeremy Livianu, to induce him to join UpHealth. Of
this amount, (i) 100,000 will vest over a three‑year period
beginning May 9, 2023, with the initial one-third vesting on May
22, 2024, and the remainder vesting quarterly thereafter on each
August 22, November 22, March 7, and May 22, subject to continued
employment by UpHealth, and (ii) 100,000 performance-based RSUs
will vest based on the achievement of specified performance goals
during the years ending December 31, 2023, 2024, and 2025, subject
to his continued employment. The awards were granted under
UpHealth’s Inducement Equity Incentive Plan as employment
inducement awards pursuant to the New York Stock Exchange
rules.
About UpHealth, Inc.
UpHealth is a global digital health company that
delivers digital-first technology, infrastructure, and services to
dramatically improve how healthcare is delivered and managed. The
UpHealth platform creates digitally enabled “care communities” that
improve access and achieve better patient outcomes at lower cost,
through digital health solutions and interoperability tools that
serve patients wherever they are, in their native language.
UpHealth’s clients include health plans, healthcare providers and
community-based organizations. For more information, please visit
https://uphealthinc.com and follow at UpHealth Inc on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of U.S. federal securities laws. Such
forward-looking statements include, but are not limited to, the
projected operation and financial performance of UpHealth, its
product offerings and developments and reception of its product by
customers, the arbitration and other legal disputes involving
Glocal, and UpHealth’s expectations, hopes, beliefs, intentions,
plans, prospects or strategies regarding the future revenue and the
business plans of UpHealth’s management team. Any statements
contained herein that are not statements of historical fact may be
deemed to be forward-looking statements. In addition, any
statements that refer to projections, forecasts, or other
characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking statements. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intends,” “may,” “might,” “plan,” “possible,” “potential,”
“predict,” “project,” “should,” “would” and similar expressions may
identify forward-looking statements, but the absence of these words
does not mean that a statement is not forward-looking. The
forward-looking statements contained in this press release are
based on certain assumptions and analyses made by the management of
UpHealth considering their respective experience and perception of
historical trends, current conditions, and expected future
developments and their potential effects on UpHealth as well as
other factors they believe are appropriate in the circumstances.
There can be no assurance that future developments affecting
UpHealth will be those anticipated. These forward-looking
statements involve a number of risks, uncertainties (some of which
are beyond the control of the parties), or other assumptions that
may cause actual results or performance to be materially different
from those expressed or implied by these forward-looking
statements, including the ability of UpHealth to service or
otherwise pay its debt obligations, the mix of services utilized by
UpHealth’s customers and such customers’ needs for these services,
market acceptance of new service offerings, the ability of UpHealth
to expand what it does for existing customers as well as to add new
customers, uncertainty with respect to how the ICA or the Indian
courts shall decide various matters that are before them or that
the Glocal Board will act in compliance with their fiduciary duties
to their shareholders, that UpHealth will have sufficient capital
to operate as anticipated, and the impact that the novel
coronavirus and the illness, COVID-19, that it causes, as well as
government responses to deal with the spread of this illness and
the reopening of economies that have been closed as part of these
responses, may have on UpHealth’s operations, the demand for
UpHealth’s products, global supply chains and economic activity in
general. Should one or more of these risks or uncertainties
materialize or should any of the assumptions being made prove
incorrect, actual results may vary in material respects from those
projected in these forward-looking statements. UpHealth undertakes
no obligation to update or revise any forward-looking statements,
whether because of new information, future events, or otherwise,
except as may be required under applicable securities laws.
Investors Relations:Shannon Devine (MZ North
America) Managing Director 203-741-8811UPH@mzgroup.us
|
UPHEALTH, INC.CONDENSED CONSOLIDATED
BALANCE SHEETS(In thousands,
unaudited) |
|
|
March 31, 2023 |
|
December 31, 2022 |
ASSETS |
Current
Assets: |
|
|
|
Cash and cash equivalents |
$ |
13,333 |
|
|
$ |
15,557 |
|
Accounts receivable, net |
|
24,432 |
|
|
|
21,851 |
|
Inventories |
|
134 |
|
|
|
161 |
|
Due from related parties |
|
— |
|
|
|
14 |
|
Prepaid expenses and other current assets |
|
3,263 |
|
|
|
2,991 |
|
Assets held for sale, current |
|
3,178 |
|
|
|
2,748 |
|
Total current assets |
|
44,340 |
|
|
|
43,322 |
|
Property and equipment,
net |
|
14,324 |
|
|
|
14,069 |
|
Operating lease right-of-use
assets |
|
6,644 |
|
|
|
7,213 |
|
Intangible assets, net |
|
30,216 |
|
|
|
31,362 |
|
Goodwill |
|
159,675 |
|
|
|
159,675 |
|
Equity investment |
|
21,200 |
|
|
|
21,200 |
|
Other assets |
|
474 |
|
|
|
438 |
|
Assets held for sale,
noncurrent |
|
61,924 |
|
|
|
62,525 |
|
Total assets |
$ |
338,797 |
|
|
$ |
339,804 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
Current
Liabilities: |
|
|
|
Accounts payable |
$ |
17,261 |
|
|
$ |
17,983 |
|
Accrued expenses |
|
41,099 |
|
|
|
38,763 |
|
Deferred revenue |
|
1,549 |
|
|
|
2,738 |
|
Due to related party |
|
166 |
|
|
|
229 |
|
Income taxes payable |
|
367 |
|
|
|
388 |
|
Related-party debt, current |
|
200 |
|
|
|
— |
|
Lease liabilities, current |
|
5,317 |
|
|
|
5,475 |
|
Other liabilities, current |
|
433 |
|
|
|
74 |
|
Liabilities held for sale, current |
|
2,975 |
|
|
|
3,319 |
|
Total current liabilities |
|
69,367 |
|
|
|
68,969 |
|
Related-party debt,
noncurrent |
|
31 |
|
|
|
281 |
|
Debt, noncurrent |
|
148,621 |
|
|
|
145,962 |
|
Deferred tax liabilities |
|
1,203 |
|
|
|
1,200 |
|
Derivative liability,
noncurrent |
|
30 |
|
|
|
56 |
|
Warrant liabilities,
noncurrent |
|
17 |
|
|
|
9 |
|
Lease liabilities,
noncurrent |
|
8,050 |
|
|
|
8,741 |
|
Other liabilities,
noncurrent |
|
201 |
|
|
|
662 |
|
Liabilities held for sale,
noncurrent |
|
7,678 |
|
|
|
7,787 |
|
Total liabilities |
|
235,198 |
|
|
|
233,667 |
|
|
|
|
|
Stockholders’
Equity: |
|
|
|
Common stock |
|
2 |
|
|
|
2 |
|
Additional paid-in
capital |
|
693,496 |
|
|
|
688,355 |
|
Treasury stock, at cost |
|
(17,000 |
) |
|
|
(17,000 |
) |
Accumulated deficit |
|
(574,292 |
) |
|
|
(566,209 |
) |
Total UpHealth, Inc., stockholders’ equity |
|
102,206 |
|
|
|
105,148 |
|
Noncontrolling interests |
|
1,393 |
|
|
|
989 |
|
Total stockholders’ equity |
|
103,599 |
|
|
|
106,137 |
|
Total liabilities and stockholders’ equity |
$ |
338,797 |
|
|
$ |
339,804 |
|
|
UPHEALTH, INC.CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS(In thousands, except per
share amounts, unaudited) |
|
|
Three Months Ended March 31, |
|
|
2023 |
|
|
|
2022 |
|
Revenues: |
|
|
|
Services |
$ |
30,941 |
|
|
$ |
25,686 |
|
Licenses and subscriptions |
|
1,936 |
|
|
|
1,781 |
|
Products |
|
9,268 |
|
|
|
8,505 |
|
Total revenues |
|
42,145 |
|
|
|
35,972 |
|
Costs of revenues: |
|
|
|
Services |
|
13,744 |
|
|
|
15,758 |
|
License and subscriptions |
|
319 |
|
|
|
233 |
|
Products |
|
5,406 |
|
|
|
5,990 |
|
Total costs of revenues |
|
19,469 |
|
|
|
21,981 |
|
Gross profit |
|
22,676 |
|
|
|
13,991 |
|
Operating expenses: |
|
|
|
Sales and marketing |
|
4,619 |
|
|
|
3,434 |
|
Research and development |
|
1,285 |
|
|
|
1,758 |
|
General and administrative |
|
11,009 |
|
|
|
11,467 |
|
Depreciation and amortization |
|
1,611 |
|
|
|
5,236 |
|
Stock-based compensation |
|
989 |
|
|
|
1,374 |
|
Lease abandonment expenses |
|
— |
|
|
|
75 |
|
Goodwill and intangible asset impairment |
|
495 |
|
|
|
6,174 |
|
Acquisition, integration, and transformation costs |
|
3,446 |
|
|
|
2,384 |
|
Total operating expenses |
|
23,454 |
|
|
|
31,902 |
|
Loss from operations |
|
(778 |
) |
|
|
(17,911 |
) |
Other expense: |
|
|
|
Interest expense |
|
(6,858 |
) |
|
|
(6,995 |
) |
Gain on fair value of derivative liability |
|
26 |
|
|
|
4,829 |
|
Gain (loss) on fair value of warrant liabilities |
|
(8 |
) |
|
|
95 |
|
Other expense, net, including interest income |
|
(17 |
) |
|
|
(16 |
) |
Total other expense |
|
(6,857 |
) |
|
|
(2,087 |
) |
Loss before income tax
benefit |
|
(7,635 |
) |
|
|
(19,998 |
) |
Income tax benefit |
|
— |
|
|
|
2,293 |
|
Net loss |
|
(7,635 |
) |
|
|
(17,705 |
) |
Less: net income (loss)
attributable to noncontrolling interests |
|
448 |
|
|
|
(260 |
) |
Net loss attributable to
UpHealth, Inc. |
$ |
(8,083 |
) |
|
$ |
(17,445 |
) |
Net loss per share
attributable to UpHealth, Inc.: |
|
|
|
Basic and diluted |
$ |
(0.51 |
) |
|
$ |
(1.21 |
) |
Weighted average shares
outstanding:(1) |
|
|
|
Basic and diluted |
|
15,730 |
|
|
|
14,454 |
|
(1)Amounts as of March 31, 2022 and before that
date differ from those published in our prior condensed
consolidated financial statements as they were retrospectively
adjusted as a result of the Reverse Stock Split. Specifically, the
number of common shares outstanding during periods before the
Reverse Stock Split are divided by the exchange ratio of 10:1, such
that each ten shares of common stock were combined and
reconstituted into one share of common stock effective December 8,
2022.
|
UPHEALTH, INC.CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS(In thousands,
unaudited) |
|
|
Three Months Ended March 31, |
|
|
2023 |
|
|
|
2022 |
|
Operating
activities: |
|
|
|
Net loss |
$ |
(7,635 |
) |
|
$ |
(17,705 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
Depreciation and amortization |
|
2,412 |
|
|
|
6,605 |
|
Amortization of debt issuance costs and discount on convertible
debt |
|
2,659 |
|
|
|
3,485 |
|
Stock-based compensation |
|
989 |
|
|
|
1,374 |
|
Impairment of property and equipment, intangible assets and
goodwill |
|
495 |
|
|
|
5,459 |
|
Provision for credit losses |
|
(122 |
) |
|
|
(342 |
) |
Loss (gain) on fair value of warrant liabilities |
|
8 |
|
|
|
(95 |
) |
Gain on fair value of derivative liability |
|
(26 |
) |
|
|
(4,829 |
) |
Deferred income taxes |
|
— |
|
|
|
(2,262 |
) |
Amortization of operating lease right-of-use assets |
|
559 |
|
|
|
— |
|
Changes in operating assets and liabilities, net of effects of
acquisitions: |
|
|
|
Accounts receivable |
|
(2,456 |
) |
|
|
3,472 |
|
Inventories |
|
26 |
|
|
|
(161 |
) |
Prepaid expenses and other current assets |
|
(632 |
) |
|
|
(577 |
) |
Accounts payable and accrued expenses |
|
1,611 |
|
|
|
3,067 |
|
Operating lease liabilities |
|
(587 |
) |
|
|
— |
|
Income taxes payable |
|
(19 |
) |
|
|
317 |
|
Deferred revenue |
|
(1,188 |
) |
|
|
(907 |
) |
Due to related parties |
|
(49 |
) |
|
|
62 |
|
Other current liabilities |
|
(84 |
) |
|
|
(34 |
) |
Net cash used in operating activities |
|
(4,039 |
) |
|
|
(3,071 |
) |
Investing
activities: |
|
|
|
Purchases of property and equipment |
|
(1,341 |
) |
|
|
(1,663 |
) |
Net cash used in investing activities |
|
(1,341 |
) |
|
|
(1,663 |
) |
Financing
activities: |
|
|
|
Proceeds from 2023 private placement, net of issuance costs of
$348 |
|
4,152 |
|
|
|
— |
|
Repayments of debt |
|
— |
|
|
|
(151 |
) |
Payments of finance and capital lease obligations |
|
(899 |
) |
|
|
(800 |
) |
Net tax withholdings from share-based compensation |
|
(3 |
) |
|
|
(68 |
) |
Distribution to noncontrolling interest |
|
(44 |
) |
|
|
— |
|
Net cash provided by (used in) provided by financing
activities |
|
3,156 |
|
|
|
(1,019 |
) |
Effect of exchange rate
changes on cash and cash equivalents |
|
— |
|
|
|
(394 |
) |
Net decrease in cash and cash
equivalents |
|
(2,224 |
) |
|
|
(6,147 |
) |
Cash and cash
equivalents, beginning of period |
|
15,557 |
|
|
|
76,801 |
|
Cash and cash
equivalents, end of period |
$ |
13,333 |
|
|
$ |
70,654 |
|
UPHEALTH, INC.NON-GAAP
FINANCIAL INFORMATION
Non-GAAP Financial Information
This press release includes financial measures that are not
calculated in accordance with accounting principles generally
accepted in the United States of America (GAAP). To supplement
UpHealth’s condensed consolidated financial statements presented in
accordance with GAAP, UpHealth presents investors with non-GAAP
financial measures, including Adjusted EBITDA.
- Adjusted EBITDA consists of net income (loss) attributable to
UpHealth, Inc., excluding depreciation and amortization;
stock-based compensation; lease abandonment expenses; goodwill and
intangible asset impairments; acquisition, integration, and
transformation costs; other income (expense); income tax benefit
(expense); net income (loss) attributable to noncontrolling
interests; and other non-recurring charges to GAAP net income
(loss) attributable to UpHealth, Inc. Other non-recurring charges
to GAAP net income (loss) attributable to UpHealth, Inc. may
include transaction expenses in connection with capital raising
transactions (whether debt, equity or equity-linked) and
acquisitions, whether or not consummated, purchase price
adjustments, the cumulative effect of a change in accounting
principles, or other expenses determined to be non-recurring.
UpHealth believes that the presentation of these non-GAAP
financial measures provides important supplemental information to
management and investors regarding financial and business trends
relating to UpHealth’s financial condition and results of
operations. Management believes that the items described above
provide an additional measure of UpHealth’s operating results and
facilitates comparisons of UpHealth’s core operating performance
against prior periods and business model objectives. This
information is provided to investors in order to facilitate
additional analyses of past, present, and future operating
performance and as a supplemental means to evaluate UpHealth’s
ongoing operations. UpHealth believes that these non-GAAP financial
measures are useful to investors in their assessment of UpHealth’s
operating performance.
Adjusted EBITDA is not calculated in accordance with GAAP, and
should be considered supplemental to, and not as a substitute for,
or superior to, financial measures calculated in accordance with
GAAP. You should not consider this measure in isolation or as a
substitute for analysis of UpHealth’s results as reported under
GAAP. UpHealth compensates for these limitations by prominently
disclosing GAAP financial measures and providing investors with
reconciliations from UpHealth’s GAAP operating results to the
non-GAAP financial measures for the relevant periods.
The accompanying tables provide more details on the GAAP
financial measures that are most directly comparable to the
non-GAAP financial measures described above and the related
reconciliations between these financial measures.
|
UPHEALTH, INC.RECONCILIATION OF GAAP TO
NON-GAAP FINANCIAL MEASURES (1)(In
thousands) |
|
|
Three Months Ended March 31, |
|
|
2023 |
|
|
|
2022 |
|
Revenues |
$ |
42,145 |
|
|
$ |
35,972 |
|
|
|
|
|
Gross margin |
|
54 |
% |
|
|
39 |
% |
|
|
|
|
Net loss attributable to
UpHealth, Inc. |
$ |
(8,083 |
) |
|
$ |
(17,445 |
) |
Net income (loss) attributable to noncontrolling interests |
|
448 |
|
|
|
(260 |
) |
Net loss |
|
(7,635 |
) |
|
|
(17,705 |
) |
Other expense |
|
6,857 |
|
|
|
2,087 |
|
Income tax benefit |
|
— |
|
|
|
(2,293 |
) |
Loss from operations |
|
(778 |
) |
|
|
(17,911 |
) |
Depreciation and amortization |
|
2,412 |
|
|
|
6,599 |
|
Stock-based compensation |
|
989 |
|
|
|
1,374 |
|
Acquisition, integration and transformation costs, and
non-recurring expenses (2) |
|
3,941 |
|
|
|
8,633 |
|
Adjusted EBITDA
(Non-GAAP) |
$ |
6,564 |
|
|
$ |
(1,305 |
) |
(1) See Non-GAAP Financial Information section for definitions
of the Company’s non-GAAP financial measures.(2) Amounts reflect
acquisition, integration and transformation costs, lease
abandonment expenses, and goodwill impairment from the condensed
consolidated statements of operations, as well as other operating
expenses considered to be non-recurring during the period.
|
UPHEALTH, INC.SEGMENT INFORMATION AND
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
(1)(In thousands) |
|
|
Three Months Ended March 31, |
|
|
2023 |
|
|
|
2022 |
|
Revenues: |
|
|
|
Integrated care management (2) |
$ |
3,873 |
|
|
$ |
2,612 |
|
Virtual care infrastructure (3)(5) |
|
17,458 |
|
|
|
15,630 |
|
Services (4) |
|
20,814 |
|
|
|
17,730 |
|
Total |
$ |
42,145 |
|
|
$ |
35,972 |
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
2023 |
|
|
|
2022 |
|
Gross Profit: |
|
|
|
Integrated care management (2) |
$ |
2,580 |
|
|
$ |
1,638 |
|
Virtual care infrastructure (3)(5) |
|
10,185 |
|
|
|
6,501 |
|
Services (4) |
|
9,911 |
|
|
|
5,852 |
|
Total |
$ |
22,676 |
|
|
$ |
13,991 |
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
2023 |
|
|
|
2022 |
|
Gross Margin %: |
|
|
|
Integrated care management (2) |
|
67 |
% |
|
|
63 |
% |
Virtual care infrastructure (3)(5) |
|
58 |
% |
|
|
42 |
% |
Services (4) |
|
48 |
% |
|
|
33 |
% |
Total |
|
54 |
% |
|
|
39 |
% |
(1) |
|
See Non-GAAP
Financial Information section for definitions of the Company’s
non-GAAP financial measures. |
|
|
|
|
|
Segment
Information |
|
|
|
|
|
The Company’s
business is organized into three operating business segments: |
|
|
|
|
|
|
|
Integrated Care Management—through the Thrasys subsidiary.Virtual
Care Infrastructure—through the Cloudbreak and Glocal (other than
for the three month period of January 1, 2023 - March 31, 2023)
subsidiaries; andServices—through the Innovations, BHS and TTC
subsidiaries. |
|
|
|
|
|
The reportable
segments are consistent with how management views the Company’s
services and products and the financial information reviewed by the
chief operating decision makers. The Company manages its businesses
as components of an enterprise for which separate information is
available and is evaluated regularly by the chief operating
decision makers in deciding how to allocate resources and assess
performance. |
|
|
|
(2) |
|
In the Integrated
Care Management segment, the Company provides its customers with an
advanced, comprehensive, and extensible technology platform,
marketed under the umbrella “SyntraNet” to manage health, quality
of care, and costs, especially for individuals with complex
medical, behavioral health, and social needs. |
|
|
|
(3) |
|
In the Virtual Care
Infrastructure segment, the Company provides technology and
process-based healthcare platforms providing its customers
comprehensive primary care, specialty consultations, and
translation services, through telemedicine, Digital Dispensaries,
and technology-based hospital centers. |
|
|
|
(4) |
|
In the Services
segment, the Company provide custom compounded medications for the
unique needs of every patient and prescriber. The Company is a
full-service pharmacy filling prescriptions from its inventory of
compounded medications, as well as drugs purchased from
manufacturers. Additionally, the Company provides inpatient and
outpatient substance abuse and mental health treatment services for
individuals with drug and alcohol addiction and other behavioral
health issues. The Company offers a complete continuum of care from
detoxification services, residential care, partial hospitalization
programs, and intensive outpatient and outpatient programs. |
|
|
|
(5) |
|
As discussed in Note
1, Organization and Business, to the Company’s condensed
consolidated financial statements, the Company deconsolidated
Glocal during the three months ended September 30, 2022; therefore,
the financial results of Glocal for the three months ended March
31, 2022 are included in our unaudited condensed consolidated
financial statements, and the financial results of Glocal as of
March 31, 2023 and for the three months then ended are not included
in our unaudited condensed consolidated financial statements. |
UpHealth (PK) (USOTC:UPHL)
Historical Stock Chart
From Jun 2024 to Jul 2024
UpHealth (PK) (USOTC:UPHL)
Historical Stock Chart
From Jul 2023 to Jul 2024